A study to evaluate the effect of hepatic insufficiency on the pharmacokinetics (PK) of ACP-196

Inclusion Criteria

• All Participants:
• - Continuous non-smokers or smokers (of fewer than 20 cigarettes/day or the equivalent). Participants must agree to consume no more than 10 cigarettes or equivalent/day from
• 24 hours before dosing and throughout the period of sample collection.
• - Women participants must be of non-child bearing status and must have negative serum pregnancy test.
• - Men of reproductible potential must be willing to abstain from heterosexual intercourse or refrain from sperm donation or use contraception during the study and through 90 days after the last dose of study drug.
• Hepatic impaired participants:
• - Body mass index (BMI) >= 19 and <= 40 kg/m^2, at screening.
• - Have medical history, physical examination, vital signs, 12-lead ECGs, and laboratory safety tests consistent with a diagnosis of hepatic impairment, but is otherwise judged to be in good health as determined by the principal investigator (PI).
• - Participant has a diagnosis of chronic (> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic
• insufficiency with features of cirrhosis due to any etiology.
• - Part 1 only: Mild - Participant’s score on the Child-Pugh scale must range from 5 to 6 (mild hepatic insufficiency) at screening. Moderate - Participant’s score on the Child-Pugh scale must range from 7 to 9 (moderate hepatic insufficiency) at screening. For participants who have compensated hepatic insufficiency while on medical therapy, they should be classified by their pretreatment parameters.
• - Part 2 only: Severe - Participant’s score on the Child-Pugh scale must range from 10 to 15 (severe hepatic insufficiency) at screening. For participant's who have compensated hepatic insufficiency while on medical therapy, they should be classified by their pretreatment parameters.
• Healthy control participants only:
• - BMI >= 19 and <= 40 kg/m^2 at screening.
• - Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs, as deemed by the PI. Liver function tests, and serum bilirubin, must be <= the upper limit of normal at screening.